Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders

Gareth J. Sanger; [Unknown] Lin Chang; Chas Bountra; Lesley A. Houghton

doi:10.1177/1756283X10369922

Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders

Gareth J. Sanger, [Unknown] Lin Chang, Chas Bountra, Lesley A. Houghton

Research output: Contribution to journal › Article › peer-review

Abstract

Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research. © The Author(s), 2010.

Original language	English
Pages (from-to)	291-305
Number of pages	14
Journal	Therapeutic Advances in Gastroenterology
Volume	3
Issue number	5
DOIs	https://doi.org/10.1177/1756283X10369922
Publication status	Published - Sept 2010

Keywords

animal models
epigenetics
IBS
mechanisms
pharmacotherapy

Access to Document

10.1177/1756283X10369922

Cite this

@article{c4c417fdc5be40788bd1fec669f36986,

title = "Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders",

abstract = "Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research. {\textcopyright} The Author(s), 2010.",

keywords = "animal models, epigenetics, IBS, mechanisms, pharmacotherapy",

author = "Sanger, {Gareth J.} and {Lin Chang}, [Unknown] and Chas Bountra and Houghton, {Lesley A.}",

year = "2010",

month = sep,

doi = "10.1177/1756283X10369922",

language = "English",

volume = "3",

pages = "291--305",

journal = "Therapeutic Advances in Gastroenterology",

publisher = "Sage Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders

AU - Sanger, Gareth J.

AU - Lin Chang, [Unknown]

AU - Bountra, Chas

AU - Houghton, Lesley A.

PY - 2010/9

Y1 - 2010/9

N2 - Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research. © The Author(s), 2010.

AB - Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research. © The Author(s), 2010.

KW - animal models

KW - epigenetics

KW - IBS

KW - mechanisms

KW - pharmacotherapy

U2 - 10.1177/1756283X10369922

DO - 10.1177/1756283X10369922

M3 - Article

VL - 3

SP - 291

EP - 305

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

IS - 5

ER -

Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders

Abstract

Keywords

Access to Document

Fingerprint

Cite this